S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:EVAX

Evaxion Biotech A/S Stock Forecast, Price & News

$3.68
-0.08 (-2.13%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.57
$3.75
50-Day Range
$3.68
$6.21
52-Week Range
$3.57
$25.04
Volume
82,175 shs
Average Volume
77,825 shs
Market Capitalization
$83.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive EVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter.


Evaxion Biotech A/S logo

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVAX
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Net Income
$-15.02 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$83.27 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/22/2022
Next Earnings (Estimated)
4/05/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

1065th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

165th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Evaxion Biotech A/S (NASDAQ:EVAX) Frequently Asked Questions

Is Evaxion Biotech A/S a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Evaxion Biotech A/S stock.
View analyst ratings for Evaxion Biotech A/S
or view top-rated stocks.

Are investors shorting Evaxion Biotech A/S?

Evaxion Biotech A/S saw a increase in short interest in December. As of December 31st, there was short interest totaling 38,700 shares, an increase of 25.6% from the December 15th total of 30,800 shares. Based on an average trading volume of 884,800 shares, the short-interest ratio is presently 0.0 days.
View Evaxion Biotech A/S's Short Interest
.

When is Evaxion Biotech A/S's next earnings date?

Evaxion Biotech A/S is scheduled to release its next quarterly earnings announcement on Tuesday, April 5th 2022.
View our earnings forecast for Evaxion Biotech A/S
.

How were Evaxion Biotech A/S's earnings last quarter?

Evaxion Biotech A/S (NASDAQ:EVAX) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.07.
View Evaxion Biotech A/S's earnings history
.

What price target have analysts set for EVAX?

3 brokerages have issued 12-month price targets for Evaxion Biotech A/S's shares. Their forecasts range from $18.00 to $23.00. On average, they anticipate Evaxion Biotech A/S's stock price to reach $20.67 in the next year. This suggests a possible upside of 461.6% from the stock's current price.
View analysts' price targets for Evaxion Biotech A/S
or view top-rated stocks among Wall Street analysts.

Who are Evaxion Biotech A/S's key executives?

Evaxion Biotech A/S's management team includes the following people:
  • Dr. Lars Aage-Staal Wegner M.D., Chief Exec. Officer (Age 46, Pay $942k)
  • Dr. Niels Iversen Moeller M.D., Co-founder & Chief Bus. Officer (Age 42, Pay $213k)
  • Mr. Andreas Holm Mattsson, Co-Founder & Chief Innovation Officer (Age 45, Pay $213k)
  • Mr. Glenn S. Vraniak, Chief Financial Officer (Age 58, Pay $1.44M)
  • Dr. Jürgen Langhärig EMBA, Ph.D., Head of Bus. Devel.
  • Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D., Chief Medical Officer (Age 53)

When did Evaxion Biotech A/S IPO?

(EVAX) raised $31 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 2,800,000 shares at a price of $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Evaxion Biotech A/S's stock symbol?

Evaxion Biotech A/S trades on the NASDAQ under the ticker symbol "EVAX."

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evaxion Biotech A/S's stock price today?

One share of EVAX stock can currently be purchased for approximately $3.68.

How much money does Evaxion Biotech A/S make?

Evaxion Biotech A/S has a market capitalization of $83.27 million.

How many employees does Evaxion Biotech A/S have?

Evaxion Biotech A/S employs 2,020 workers across the globe.

What is Evaxion Biotech A/S's official website?

The official website for Evaxion Biotech A/S is www.evaxion-biotech.com.

Where are Evaxion Biotech A/S's headquarters?

Evaxion Biotech A/S is headquartered at BREDGADE 34E, COPENHAGEN K G7, 1260.

How can I contact Evaxion Biotech A/S?

Evaxion Biotech A/S's mailing address is BREDGADE 34E, COPENHAGEN K G7, 1260. The company can be reached via phone at 45-5353-1850 or via email at [email protected].


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.